{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Renal&page=20", "query": { "condition": "Carcinoma, Renal", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1550, "total_pages": 155, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Renal&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Renal&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T16:19:07.501Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04147494", "title": "Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Carcinoma", "Colon Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Kidney Carcinoma", "Lung Carcinoma", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Solid Neoplasm", "Uterine Corpus Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Gallium Ga 68-labeled PSMA-11", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "18F-FDG", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-11-05", "completion_date": "2031-10-17", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04147494" }, { "nct_id": "NCT00039429", "title": "Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "atrasentan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 180, "start_date": "2003-07-14", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 177, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039429" }, { "nct_id": "NCT00301847", "title": "Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2005-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 12, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301847" }, { "nct_id": "NCT04626518", "title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Belzutifan", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Favezelimab/Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 263, "start_date": "2020-12-17", "completion_date": "2026-07-23", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626518" }, { "nct_id": "NCT02885649", "title": "Enzalutamide Before Surgery in Treating Patients With Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Stage I Renal Cell Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-12-05", "completion_date": "2020-03-02", "has_results": false, "last_update_posted_date": "2021-09-16", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02885649" }, { "nct_id": "NCT04309617", "title": "Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 618, "start_date": "2019-07-31", "completion_date": "2020-04-28", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04309617" }, { "nct_id": "NCT00445523", "title": "Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "TroVax® (Immunological Vaccine Therapy)", "type": "BIOLOGICAL" }, { "name": "Interferon-alpha", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-05", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445523" }, { "nct_id": "NCT04596033", "title": "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Small-cell Lung Cancer", "Cutaneous Squamous Cell Carcinoma", "Anal Squamous Cell Carcinoma", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "GEN-011", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-11-11", "completion_date": "2022-06-27", "has_results": false, "last_update_posted_date": "2022-07-15", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04596033" }, { "nct_id": "NCT00072150", "title": "Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Stage III Bladder Cancer", "Stage III Urethral Cancer", "Stage IV Bladder Cancer", "Stage IV Urethral Cancer", "Transitional Cell Carcinoma of the Bladder", "Ureter Cancer" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072150" }, { "nct_id": "NCT02535533", "title": "SLM + Axitinib for Clear Cell RCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)" ], "interventions": [ { "name": "Selenomethionine (SLM)", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mohammed Milhem", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2016-01", "completion_date": "2025-04-04", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-15T16:19:07.501Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02535533" } ] }